APA (7th ed.) Citation

JK, S., G, A., L, C., J, T., R, F., I, D., . . . B, N. (2020). Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. Vaccines, 8(4), . https://doi.org/10.3390/vaccines8040670

Chicago Style (17th ed.) Citation

JK, Schwarze, Awada G, Cras L, Tijtgat J, Forsyth R, Dufait I, Tuyaerts S, Van Riet I, and Neyns B. "Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial." Vaccines 8, no. 4 (2020). https://doi.org/10.3390/vaccines8040670.

MLA (9th ed.) Citation

JK, Schwarze, et al. "Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial." Vaccines, vol. 8, no. 4, 2020, https://doi.org/10.3390/vaccines8040670.